Four-arm PEG cross-linked hyaluronic acid hydrogels containing PEGylated apoptotic TRAIL protein for treating pancreatic cancer

Acta Biomaterialia

Volumn 10, Issue 1, 2014, Pages 142-150

  Byeon, Hyeong Jun ^a   Choi, Seong Ho ^a   Choi, Ji Su ^a   Kim, Insoo ^a   Shin, Beom Soo ^b   Lee, Eun Seong ^c   Park, Eun Seok ^a   Lee, Kang Choon ^a   Youn, Yu Seok ^a  

^a Sungkyunkwan University   (South Korea)

^b Catholic University of Daegu   (South Korea)

^c The Catholic University of Korea   (South Korea)

Author keywords

Four arm PEG; Hyaluronic acid; Hydrogels; Pancreatic cancer; TRAIL

Indexed keywords

CELL DEATH; DISEASES; HYDROGELS; MAMMALS; ORGANIC ACIDS; THERMOGRAPHY (IMAGING); TUMORS;

ANTI-TUMOR EFFICACY; ANTITUMOR EFFECT; APOPTOTIC ACTIVITY; CROSSLINKER; FOUR-ARM POLYETHYLENE GLYCOL; HYALURONIC ACID HYDROGELS; IN-VIVO; PANCREATIC CANCERS; PEGYLATED; TRAIL;

HYALURONIC ACID;

HYALURONIC ACID; MACROGOL; PEGYLATED TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CROSS LINKING; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROGEL; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; TUMOR VOLUME; TUMOR XENOGRAFT;

AGOUTI PACA; MUS;

FOUR-ARM PEG; HYALURONIC ACID; HYDROGELS; PANCREATIC CANCER; TRAIL;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARBOCYANINES; CELL LINE, TUMOR; CROSS-LINKING REAGENTS; HUMANS; HYALURONIC ACID; HYDROGELS; MALE; MICE; MICE, INBRED ICR; PANCREATIC NEOPLASMS; POLYETHYLENE GLYCOLS; PROTEIN STABILITY; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84888644574     PISSN: 17427061     EISSN: 18787568     Source Type: Journal    
DOI: 10.1016/j.actbio.2013.08.046     Document Type: Article

References (38)

1. R.T. Greenlee, M.B. Hill-Harmon, T. Murray, and M. Thun Cancer statistics, 2001 CA Cancer J Clin 51 2001 15 36
2. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, et al. SEER Cancer Statistics Review, 1975-2002. National Cancer Institute; 2005.
3. A. Sultana, C. Tudur Smith, D. Cunningham, N. Starling, D. Tait, and J.P. Neoptolemos, et al. Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy Br J Cancer 96 2007 1183 1190
4. X. Yu, Y. Zhang, C. Chen, Q. Yao, and M. Li Targeted drug delivery in pancreatic cancer Biochim Biophys Acta 1805 2010 97 104
5. W.K. Bae, M.S. Park, J.H. Lee, J.E. Hwang, H.J. Shim, and S.H. Cho Docetaxel-loaded thermoresponsive conjugated linoleic acid-incorporated poloxamer hydrogel for the suppression of peritoneal metastasis of gastric cancer Biomaterials 34 2013 1433 1441
6. M. Markman Intraperitoneal drug delivery of antineoplastics Drugs 61 2001 1057 1065
7. G. Bajaj, M.R. Kim, S.I. Mohammed, and Y. Yeo Hyaluronic acid-based hydrogel for regional delivery of paclitaxel to intraperitoneal tumors J Control Release 158 2012 386 392
8. H.T. Ta, C.R. Dass, I. Larson, P.F. Choong, and D.E. Dunstan A chitosan-dipotassium orthophosphate hydrogel for the delivery of doxorubicin in the treatment of osteosarcoma Biomaterials 30 2009 3605 3613
9. R. De Souza, P. Zahedi, E.H. Moriyama, C.J. Allen, B.C. Wilson, and M. Piquette-Miller Continuous docetaxel chemotherapy improves therapeutic efficacy in murine models of ovarian cancer Mol Cancer Ther 9 2010 1820 1830
10. P. Zahedi, R. De Souza, M. Piquette-Miller, and C. Allen Chitosan-phospholipid blend for sustained and localized delivery of docetaxel to the peritoneal cavity Int J Pharm 377 2009 76 84
11. E.A. Ho, P.L. Soo, C. Allen, and M. Piquette-Miller Impact of intraperitoneal, sustained delivery of paclitaxel on the expression of P-glycoprotein in ovarian tumors J Control Release 117 2007 20 27
12. P. Zahedi, R. De Souza, L. Huynh, M. Piquette-Miller, and C. Allen Combination drug delivery strategy for the treatment of multidrug resistant ovarian cancer Mol Pharm 8 2011 260 269
13. B.M. Yan, and J. Van Dam Endoscopic ultrasound-guided intratumoural therapy for pancreatic cancer Can J Gastroenterol 22 2008 405 410
14. E.C. Verna, and V. Dhar Endoscopic ultrasound-guided fine needle injection for cancer therapy: the evolving role of therapeutic endoscopic ultrasound Ther Adv Gastroenterol 1 2008 103 109
15. T.S. Griffith, and D.H. Lynch TRAIL: a molecule with multiple receptors and control mechanisms Curr Opin Immunol 10 1998 559 563
16. L.E. French, and J. Tschopp The TRAIL to selective tumor death Nat Med 5 1999 146 147
17. A. Ashkenazi, R.C. Pai, S. Fong, S. Leung, D.A. Lawrence, and S.A. Marsters Safety and antitumor activity of recombinant soluble Apo2 ligand J Clin Invest 104 1999 155 162
18. H.N. LeBlanc, and A. Ashkenazi Apo2L/TRAIL and its death and decoy receptors Cell Death Differ 10 2003 66 75
19. R. Saito, J.R. Bringas, A. Panner, M. Tamas, R.O. Pieper, and M.S. Berger Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model Cancer Res 64 2004 6858 6862
20. W. Roth, S. Isenmann, U. Naumann, S. Kugler, M. Bahr, and J. Dichgans Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity Biochem Biophys Res Commun 265 1999 479 483
21. S.M. Lim, T.H. Kim, H.H. Jiang, C.W. Park, S. Lee, and X. Chen Improved biological half-life and anti-tumor activity of TNF-related apoptosis-inducing ligand (TRAIL) using PEG-exposed nanoparticles Biomaterials 32 2011 3538 3546
22. H.H. Jiang, T.H. Kim, S. Lee, X. Chen, Y.S. Youn, and K.C. Lee PEGylated TNF-related apoptosis-inducing ligand (TRAIL) for effective tumor combination therapy Biomaterials 32 2011 8529 8537
23. T.H. Kim, H.H. Jiang, C.W. Park, Y.S. Youn, S. Lee, and X. Chen PEGylated TNF-related apoptosis-inducing ligand (TRAIL)-loaded sustained release PLGA microspheres for enhanced stability and antitumor activity J Control Release 150 2011 63 69
24. T.H. Kim, Y.S. Youn, H.H. Jiang, S. Lee, X. Chen, and K.C. Lee PEGylated TNF-related apoptosis-inducing ligand (TRAIL) analogues: pharmacokinetics and antitumor effects Bioconjug Chem 22 2011 1631 1637
25. S. Bae, K. Ma, T.H. Kim, E.S. Lee, K.T. Oh, and E.S. Park Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types Biomaterials 33 2012 1536 1546
26. T. Caykara, M. Bulut, N. Dilsiz, and Y. Akyuz Macroporous poly(acrylamide) hydrogels: swelling and shrinking behaviors J Macromol Sci Pure Appl Chem 43 2006 889 897
27. I. Kim, H.J. Byeon, T.H. Kim, E.S. Lee, K.T. Oh, and B.S. Shin Doxorubicin-loaded highly porous large PLGA microparticles as a sustained- release inhalation system for the treatment of metastatic lung cancer Biomaterials 33 2012 5574 5583
28. X. Xu, A.K. Jha, D.A. Harrington, M.C. Farach-Carson, and X. Jia Hyaluronic acid-based hydrogels: from a natural polysaccharide to complex networks Soft Matter 8 2012 3280 3294
29. J.A. Burdick, and G.D. Prestwich Hyaluronic acid hydrogels for biomedical applications Adv Mater 23 2011 H41 56
30. R.P. Thomas, B.J. Farrow, S. Kim, M.J. May, M.R. Hellmich, and B.M. Evers Selective targeting of the nuclear factor-kappaB pathway enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated pancreatic cancer cell death Surgery 132 2002 127 134
31. F. Ozawa, H. Friess, J. Kleeff, Z.W. Xu, A. Zimmermann, and M.S. Sheikh Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer Cancer Lett 163 2001 71 81
32. S.Y. Chae, T.H. Kim, K. Park, C.H. Jin, S. Son, and S. Lee Improved antitumor activity and tumor targeting of NH(2)-terminal-specific PEGylated tumor necrosis factor-related apoptosis-inducing ligand Mol Cancer Ther 9 2010 1719 1729
33. S.Y. Chae, Y.G. Chun, S. Lee, C.H. Jin, E.S. Lee, and K.C. Lee Pharmacokinetic and pharmacodynamic evaluation of site-specific PEGylated glucagon-like peptide-1 analogs as flexible postprandial-glucose controllers J Pharm Sci 98 2009 1556 1567
34. Y.S. Youn, M.J. Shin, S.Y. Chae, C.H. Jin, T.H. Kim, and K.C. Lee Biological and physicochemical evaluation of the conformational stability of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) Biotechnol Lett 29 2007 713 721
35. E.J. Park, D.H. Na, and K.C. Lee In vitro release study of mono-PEGylated growth hormone-releasing peptide-6 from PLGA microspheres Int J Pharm 343 2007 281 283
36. M. Diwan, and T.G. Park Stabilization of recombinant interferon-a by pegylation for encapsulation in PLGA microspheres Int J Pharm 252 2003 111 122
37. M. Diwan, and T.G. Park Pegylation enhances protein stability during encapsulation in PLGA microspheres J Control Release 73 2001 233 244
38. E.J. Oh, K. Park, K.S. Kim, J. Kim, J.A. Yang, and J.H. Kong Target specific and long-acting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic acid derivatives J Control Release 141 2010 2 12